Aureomycin, the yellow antibiotic substance produced by the actinomycete Streptomyces aureofaciens, has had extensive clinical use since its discovery by Duggar in 1948.1 It has a wide spectrum of chemotherapeutic activity, and its use is accompanied by a relative lack of harmful effects. Aureomycin is effective not only against many gram-positive and gram-negative bacteria, including penicillin-resistant and streptomycin-resistant strains, but also against Rickettsia and certain viruses. Furthermore, organisms show little tendency to develop resistance to aureomycin.
Intramuscular injection of aureomycin results in local irritation, unpredictable blood levels and unsatisfactory therapeutic results.2 Oral administration results in satisfactory therapeutic results but is accompanied by high incidence of gastrointestinal upsets, including loss of appetite, nausea, vomiting and epigastric pain. Effects directed toward reduction of these gastrointestinal upsets include the use of more purified preparations and administration with adjuncts such as gastric antacids and milk. The effectiveness of an aluminum hydroxide gel